gyki 52466 has been researched along with Brain Disorders in 2 studies
GYKI 52466: an AMPA (non-NMDA) receptor antagonist; structure given in first source
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nandhu, MS | 1 |
| Paul, J | 1 |
| Mathew, J | 1 |
| Peeyush Kumar, T | 1 |
| Paulose, CS | 1 |
| Li, H | 1 |
| Buchan, AM | 1 |
2 other studies available for gyki 52466 and Brain Disorders
| Article | Year |
|---|---|
GYKI-52466: a potential therapeutic agent for glutamate-mediated excitotoxic injury in Cerebral Palsy.
Topics: Benzodiazepines; Brain Diseases; Cerebral Palsy; Glutamic Acid; Humans; Models, Neurological; Recept | 2010 |
Treatment with an AMPA antagonist 12 hours following severe normothermic forebrain ischemia prevents CA1 neuronal injury.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anti-Anxiety Agents; Benzodiazepi | 1993 |